Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22099095 | 1.00 | THRB (0.39) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099238 | 0.99 | THRB (0.40) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099480 | 0.98 | THRB (0.41) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099086 | 0.98 | THRB (0.41) | THRBAPPTSHRHTTTDP1 | |
| SCHEMBL22099125 | 0.97 | THRB (0.44) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099475 | 0.97 | THRB (0.44) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099076 | 0.97 | THRB (0.44) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099460 | 0.97 | THRB (0.41) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099508 | 0.96 | THRB (0.44) | THRBAPPALDH1A1CYP3A4TSHR | |
| SCHEMBL22099131 | 0.96 | THRB (0.42) | THRBAPPALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190016-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190016-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CNTN1, HVCN1, PKN1 | THRB 4634/4885APP 165/4885ALDH1A1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.